Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.